^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Small Lymphocytic Lymphoma
    Drug:Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens…Acalabrutinib ± obinutuzumab
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Lymphocytic Leukemia)
    New
    Excerpt:
    acalabrutinib (Calquence) is accepted for restricted use within NHSScotland....as monotherapy for the treatment of adult patients with previously untreated CLL who have a 17p deletion or TP53 mutation and in whom chemoimmunotherapy is unsuitable.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

    Excerpt:
    ...- Relapsed/Refractory CLL or treatment naïve CLL patients with 17p deletion, TP53 mutation, or NOTCH1 mutation...
    Trial ID:
    15-H-0016